Don't Rely on Omega-3s for Cardiovascular Benefits
January 2021
Do omega-3 fatty acid supplements reduce CV risk?
Mounting evidence suggests they don't...despite prior evidence with Rx Vascepa (icosapent ethyl), a form of EPA (eicosapentaenoic acid).
Vascepa 2 g BID is approved to reduce CV risk in some high-risk patients with moderately elevated triglycerides despite statins.
Get unlimited access through an Enterprise license
Hospital Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 300+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Not sold to individuals